Bone morphogenetic protein 3 (BMP3)

Bone morphogenetic protein 3 (BMP3) is a secreted extracellular ligand and member of the transforming growth factor beta (TGF-β) superfamily[5]. Uniquely among bone morphogenetic proteins, BMP3 acts as an antagonist to other BMPs in the differentiation of osteogenic progenitors, thereby inhibiting bone and cartilage formation and negatively regulating bone density[2][3][5]. BMP3 is highly expressed in fractured tissues and is primarily produced by osteoblasts and osteocytes[3]. At the molecular level, BMP3 functions as a disulfide-linked homodimer, signals through type II serine/threonine kinase receptors (notably Activin type II receptors), and transduces signals via the SMAD-dependent pathway to influence gene transcription[1][5]. BMP3 is also referred to as osteogenin. Hypermethylation of the BMP3 promoter is a frequent event in colorectal cancer and may serve as a clinically useful epigenetic biomarker[2]. As of current knowledge, BMP3 is not therapeutically targeted by any approved drugs.

Other names

Bone morphogenetic protein 3ABMP3ABMP-3BMP-3AOsteogeninosteogeninbone morphogenetic protein 3 (osteogenic)